• Radiopharm Theranostics flagged initial first-in-human findings from Phase 0/1 HEAT trial of 177Lu-RAD202 in HER2-positive advanced solid tumors, with results scheduled for poster presentation at AACR 2026 on April 20.
• Early readout showed encouraging tumor targeting with a generally favorable safety profile in lowest-dose cohort, supporting continued clinical development.
• Trial oversight committee cleared dose escalation, moving program to next higher dose cohort at 130 mCi.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Radiopharm Theranostics Ltd. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202604200700PRIMZONEFULLFEED1001176656) on April 20, 2026, and is solely responsible for the information contained therein.